Fertility technology company Overture Life has secured a $20.6 million strategic funding round led by returning investor Overwater Ventures with participation from GV (formerly Google Ventures) and Khosla Ventures. The new capital brings the company’s total funding to $57 million and will support clinical trials for its DaVitri platform as it prepares for FDA clearance.
Overture has simultaneously announced receiving a CLIA (Clinical Laboratory Improvement Amendments) license for its U.S. operations, validating its m|z metabolomic test for non-invasive embryo selection. This regulatory milestone strengthens the company’s position as it commercializes its automated fertility solutions.
DaVitri, the company’s embryology platform, addresses inefficiencies in the IVF process by automating egg freezing (vitrification) and embryo warming procedures that traditionally require manual precision. Already available in several markets outside the U.S., the desk-sized system standardizes these procedures with precise timing and controlled cryoprotectant exposure, potentially improving oocyte survival rates.
“This new funding allows us to accelerate our expansion of IVF capabilities and demonstrates the value of operating within a CLIA-licensed laboratory environment, highlighting not only our technological leadership but also our commitment to the highest standards of clinical validation,” said Hans Gangeskar, CEO of Overture Life. “DaVitri has already shown potential to significantly increase clinical throughput while ensuring reproducibility in critical freezing and warming processes, allowing embryologists to prioritize personalized patient care.”
In 2023, Overture announced the first babies born via robotic conception. The company integrates robotics, microfluidics, and AI-powered analytics to modernize embryology procedures, with the goal of making fertility preservation and IVF more accessible by reducing costs and increasing reliability.
“Automation and standardization in the embryology lab is an exciting step towards optimizing efficiency and efficacy in IVF. It allows us to deliver consistent and excellent care, while still giving us the flexibility to fine-tune protocols for our patients,” noted Dr. Serena H. Chen, a Reproductive Endocrinologist at CCRM Fertility of NJ. “We’re very excited about the potential to serve more patients by increasing lab capacity without sacrificing quality.”
The company’s focus on standardizing egg freezing procedures has implications for women’s reproductive options. By potentially improving the clinical predictability and success rates of egg freezing while lowering costs, Overture’s technology could expand access to fertility preservation.
“Fertility intersects healthcare, economics, and the most personal of human wishes,” said Kristina Simmons, Founder and Managing Partner at Overwater Ventures. “Women have long faced irreversible biological timelines, and by making egg freezing cheaper, easier, and more clinically effective and predictable, it allows women and families to regain choice and opportunity.”
With R&D operations in Spain and growing U.S. presence, Overture is positioning its technology to address the global fertility services market, where demand continues to increase while traditional IVF methods face capacity and cost constraints.
